TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

NCT01485991 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

771

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: TMC435
DRUG: TVR

Sponsor

Janssen R&D Ireland